Clinical utility and safety of MultiHance (R) in magnetic resonance imaging of liver cancer: Results of multicenter studies in Europe and the USA

Citation
B. Hamm et al., Clinical utility and safety of MultiHance (R) in magnetic resonance imaging of liver cancer: Results of multicenter studies in Europe and the USA, J COMPUT AS, 23, 1999, pp. S53-S60
Citations number
26
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
ISSN journal
03638715 → ACNP
Volume
23
Year of publication
1999
Supplement
1
Pages
S53 - S60
Database
ISI
SICI code
0363-8715(199911)23:<S53:CUASOM>2.0.ZU;2-8
Abstract
MultiHance(R) (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) is a novel gadolinium-based contrast agent which has recently been made co mmercially available in Europe for magnetic resonance imaging of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a liver-specific agent and has been shown in numerous c linical trials to improve the impact of magnetic resonance imaging for both the detection and characterization of focal liver masses. The present arti cle briefly summarizes the safety and efficacy results of Phase I, II and I II clinical studies carried out in almost 800 patient and non-patient volun teers in both Europe and the USA.